A new gene therapy to treat melanoma
Official title: A novel gene-based immunotherapy inducing melanoma destruction
Funded at University of Texas El Paso · NIH-11056101 · Data updated 2026-11-12
This study is testing a new treatment for melanoma that uses your own immune system to help fight the cancer, and it’s looking for patients who want to try this exciting approach.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Texas El Paso NIH-funded |
| Lab location | 1 site (El Paso, United States) |
| Project start | March 15, 2024 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $208,281 |
| NIH project number | 5R21CA283583-02 |
| Project ID | NIH-11056101 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with advanced melanoma who have not responded to existing therapies.
✕Less likely to help
Patients with early-stage melanoma or those who have not been diagnosed with melanoma may not benefit from this research.
What this research studies
This research investigates a novel gene-based immunotherapy aimed at destroying melanoma cells. It utilizes autologous melanoma vaccines that harness the body's own anti-a-Gal antibodies to enhance the immune response against tumor-specific antigens. By improving the immunogenicity of these antigens, the therapy seeks to activate the immune system more effectively to target and eliminate melanoma cells. Patients may have the opportunity to participate in trials that explore this innovative approach to melanoma treatment.
Why it matters
Potential benefit: If successful, this research could provide a new and effective treatment option for patients with advanced melanoma.
How similar studies have gone: While the use of gene-based immunotherapies is a growing field, this specific approach utilizing anti-a-Gal antibodies is novel and has not been extensively tested in melanoma treatment.
Where this research is happening
-
University of Texas El Paso
El Paso, United States Active
Researchers
- Principal investigator: Michael, Katja — University of Texas El Paso
- Study coordinator: Michael, Katja
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
New approach to overcome resistance to immunotherapy in melanoma
A new strategy targets a key pathway in melanoma to boost the effectiveness of immune-based therapies for patients whose cancer resists treatment.
-
Multivalent circular mRNA vaccines for melanoma immunotherapy
A cancer vaccine approach using tiny circular mRNA vaccines aimed at boosting immune responses against melanoma in combination with existing immunotherapies.
-
Lymph Node–Targeted Co-delivery for Melanoma Immunotherapy
Aimed at improving melanoma treatment, this project tests a targeted vaccine approach that helps the body’s immune system better attack skin cancer.
-
Multifunctional nanoparticles to boost melanoma immunotherapy
A new nanoparticle approach using ultrasound-triggered systems aims to make melanoma immunotherapy work better for patients who don’t respond well to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.